Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema

John Doukas, Sankaranarayana Mahesh, Naoyasu Umeda, Shu Kachi, Hideo Akiyama, Katsutoshi Yokoi, Jon Cao, Zoe Chen, Luis Dellamary, Betty Tam, Adrienne Racanelli-Layton, John Hood, Michael Martin, Glenn Noronha, Richard Soll, Peter A. Campochiaro

Research output: Contribution to journalArticlepeer-review

66 Scopus citations


Age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions are complicated by neovascularization and macular edema. Multi-targeted kinase inhibitors that inhibit select growth factor receptor tyrosine kinases and/or components of their downstream signaling cascades (such as Src kinases) are rationale treatment strategies for these disease processes. We describe the discovery and characterization of two such agents. TG100572, which inhibits Src kinases and selected receptor tyrosine kinases, induced apoptosis of proliferating endothelial cells in vitro. Systemic delivery of TG100572 in a murine model of laser-induced choroidal neovascularization (CNV) caused significant suppression of CNV, but with an associated weight loss suggestive of systemic toxicity. To minimize systemic exposure, topical delivery of TG100572 to the cornea was explored, and while substantial levels of TG100572 were achieved in the retina and choroid, superior exposure levels were achieved using TG100801, an inactive prodrug that generates TG100572 by de-esterification. Neither TG100801 nor TG100572 were detectable in plasma following topical delivery of TG 100801, and adverse safety signals (such as weight loss) were not observed even with prolonged dosing schedules. Topical TG100801 significantly suppressed laser-induced CNV in mice, and reduced fluorescein leakage from the vasculature and retinal thickening measured by optical coherence tomography in a rat model of retinal vein occlusion. These data suggest that TG100801 may provide a new topically applied treatment approach for ocular neovascularization and retinal edema.

Original languageEnglish (US)
Pages (from-to)29-37
Number of pages9
JournalJournal of Cellular Physiology
Issue number1
StatePublished - Jul 2008

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema'. Together they form a unique fingerprint.

Cite this